A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses

Maximum observed concentration (Cmax)

Time frame: Up to Day 23

Time of maximum observed concentration (Tmax)

Time frame: Up to Day 23

Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))

Time frame: Up to Day 23

Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

Time frame: Up to Day 23

Area under the concentration-time curve in 1 dosing interval (AUC(TAU))

Time frame: Up to Day 23

Concentration at the end of a dosing interval (Ctau)

Time frame: Up to Day 23

Apparent total body clearance (CLT/F)

Time frame: Up to Day 23

Effective elimination half-life during dosing interval (T-HALF(eff))

Time frame: Up to Day 23

Number of participants with Treatment Emergent Adverse Events (TEAEs)

Time frame: Up to 30 days after final dose of study intervention

Number of participants with Serious Adverse Events (SAEs)

Time frame: Up to 30 days after final dose of study intervention

Number of participants with Adverse Events of Special Interest (AESIs)

Time frame: Up to 30 days after final dose of study intervention

Number of participants with AEs leading to discontinuation

Time frame: Up to 30 days after final dose of study intervention

Columbia-Suicide Severity Rating Scale (C-SSRS)

Time frame: Up to Day 14